Micro-Cap Biotech Rallies After Breakthrough Melanoma Therapy Results

Sponsored:

Monday, October 20, 2025

On a risk-on day in the broader markets, one micro-cap biotech is standing out, as the company reports a strong patient response rate in its first-in-human THT cancer therapy study. Shares are surging on the news.

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) announced earlier this morning that the company had encouraging results from its first-in-human study using its Targeted Hyperthermia Therapy (THT) to treat advanced, immunotherapy-resistant cutaneous metastatic melanoma. In the early-stage feasibility trial, ten patients who had not responded to standard immunotherapies received THT treatment on days one and eight. By day 15, eight out of ten participants showed a positive response—six achieving complete tumor clearance confirmed through biopsy, and two showing partial improvement—demonstrating an impressive 80% overall response rate.

David Regan, Sona's CEO, commented, "These favorable results—demonstrated in the majority of treated patients—show that Sona's THT therapy has successfully eliminated melanoma in tumors where leading treatments had previously failed. This outcome has exceeded our expectations and delivered on our commitment to investors to produce human efficacy data quickly. Based on findings from this study, we are preparing for a Canadian clinical trial that will provide deeper insights into the biological potential of our THT as we prepare to expand its clinical application into a broader range of solid tumor cancers. An application for an investigational testing authorization ("ITA") has been made to Health Canada to permit this next clinical study for which we have already received research ethics board approval."

Shares of SONA are currently up 19.05% at $0.75, while U.S. listed shares rally 25.45% at $0.56 in early-afternoon trading.

Sponsored: